Topikal Finasterid Losyon ve Krem

[Miracle]

dutasın yarılanma ömrü ne kadar ki ?

Bazı kaynaklarda 28 bazılarında 35 gün.

[Invincible]

Yalnız şöyle bir şey var, belki yarılanma ömrü uzun fakat sisteme giren dut çok çok az, ben kan dolaşımına katılıp dht inhibe etmesiyle değil doğrudan scalpta inhibe etmesiyle fayda sağladığını düşünüyorum.

Önemli olan scalptan ne kadar zamanda atıldığı ve bununla ilgili elimizde ne yazık ki herhangi bir bilgi yok.

min+fin kullanan biri olursa aralarında ki farkı da net bir şekilde görebiliriz.

[Miracle]

Yalnız şöyle bir şey var, belki yarılanma ömrü uzun fakat sisteme giren dut çok çok az, ben kan dolaşımına katılıp dht inhibe etmesiyle değil doğrudan scalpta inhibe etmesiyle fayda sağladığını düşünüyorum.

Önemli olan scalptan ne kadar zamanda atıldığı ve bununla ilgili elimizde ne yazık ki herhangi bir bilgi yok.

min+fin kullanan biri olursa aralarında ki farkı da net bir şekilde görebiliriz.

Evet direkt zaten folikül ar enzimini inhibe ediyor fakat zamanla sistemde ne emiliyor ne birikiyor bir veri yok ne yazıkki. Scalpta dolaşım yavaş ve çok doğru bir dozla etkin iletim le ar enzimini bozup dejenere olmuş bir dutas molekülü belki sıfır zararla atılmayı bekler. Bunlar tabiki teori ama mantıksız değil.

[bendeniz]

miracle gecen bir calısma gördüm moralim bozuldu topikal finanstreid agız yoluyla alınan ile topikal aynı derecede atki ediyormus ama topikalde de dht kan duzeyi aynıymış yani yan etki duzeyi aynıymıs sen saclptan emilim vs işini biliyosun ne diyosun bu konuya görüşlerin neler?

[Miracle]

miracle gecen bir calısma gördüm moralim bozuldu topikal finanstreid agız yoluyla alınan ile topikal aynı derecede atki ediyormus ama topikalde de dht kan duzeyi aynıymış yani yan etki duzeyi aynıymıs sen saclptan emilim vs işini biliyosun ne diyosun bu konuya görüşlerin neler?

O çalışmayı biliyorum bu çalışma algının ne kadar kırılgan olduğunu ve manüplasyona açık olduğunu gösteriyor. Bu çalışmanın niyetini ya da güveninirliğini sorgulamıyorum yanlış anlaşılmasın demek istedsiğim tam olarak şu ; yapılan çalışmada ki losyonda ki finasterid oranı o kadar yüksek ki % 5-10 emilim oranında bile 1 mg ve üstü emilim oluyor haliyle sisteme scalptan arta kalan karışıyor bu da serum düzeyini aynı oral gibi etkiliyor.Finasterid öyle güçlü ki 0.25 mg bile vücutta 1 mg a yakın etki gösteriyor ve gücüne rağmen istersen 10 mg al %65 total dht blokajı geçemiyor. Yani dozlama çok önemli mesela dutas minox losyonunda o kadar hesaplama yaptım ve 10 adet avodarta kadar güvenli çıktı emilne/sistemik oranı boşuna öneride bulunmadık günlük sıkılan miktar emilen oran emilenin total serum dht blokajı vs.... Topikal finasterid uygun dozda etkili olur ve dozlaması gayet kolay yapılabilir ince nüanslara dikkat edilmeli sadece.

[bendeniz]

o calısmada ne kadar finanstreid kullanıldıgı bilmiyorum ama işte moralim bozuldu bilirsin usta ugrasıyoruz ugrasıyoruz pat bir arastırma cıkıyor moral alt ust birde 14 senedir ugrasıyoruz bu calısmayı gorunce haydaaaa diyorum ama senin dedigin gibi mantıklı olabilir ne kadar finanstreid kullandılar bakmadım birde baska bişey daha soracam sprio sadece sac dibindeki dht blokluyormus bu konuda ne dusunuyosun usta sadece sac dibindeki dht bloklayan maddeler hakkında bilgin görüşün nedir? yoksa yukarda yazdıgın gibi hepsi scalpta bloklar mesele oranmı miktarmı?

[Miracle]

o calısmada ne kadar finanstreid kullanıldıgı bilmiyorum ama işte moralim bozuldu bilirsin usta ugrasıyoruz ugrasıyoruz pat bir arastırma cıkıyor moral alt ust birde 14 senedir ugrasıyoruz bu calısmayı gorunce haydaaaa diyorum ama senin dedigin gibi mantıklı olabilir ne kadar finanstreid kullandılar bakmadım birde baska bişey daha soracam sprio sadece sac dibindeki dht blokluyormus bu konuda ne dusunuyosun usta sadece sac dibindeki dht bloklayan maddeler hakkında bilgin görüşün nedir? yoksa yukarda yazdıgın gibi hepsi scalpta bloklar mesele oranmı miktarmı?

Dht Bloklamaz androjen reseptörlerine bağlanır dht dahil androjenlerin bağlanmasını engeller yani işi hormonla değil hormonun yuvasıyla. Miktarına gelince bu etken yarışmalı bağlanır yani ortamda hepsi var hangisi önce ulaşırsa çoksa o bağlanır reseptöre fazla kullanırsan çoğu reseptörü kapatırsın. Bahsettiğin çalışmayı atarmısın hesaplamaları yapalım bakalım baktığım çalışmamı ?

[bendeniz]

ingilizcem olmadıgı icin calısmaları karıstırabalirirm sunlar var dun gece baskmıstım inşallah bulurum
An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
Arca E 1 , Açikgöz G , Taştan HB , Köse O , Kurumlu Z .
Author information
1 Department of Dermatology, Gülhane Military Medical Academy, School of Medicine, Etlik-Ankara, Turkey. earca@gata.edu.tr
Abstract
BACKGROUND AND AIM:
Androgenetic alopecia (AGA) is undoubtedly the most common form of hair loss in males. It is a condition which may cause cosmetic and psychosocial problems in androgen-dependent cases. In this open, randomized and comparative study we evaluated the efficacy of oral finasteride and 5% topical minoxidil treatment for 12 months in 65 male patients with mild to severe AGA.

METHODS:
We randomly assigned 40 (61.53%) patients to receive 1 mg/day oral finasteride for 12 months, and 25 (38.47%) patients applied 5% topical minoxidil solution twice daily for 12 months.

RESULTS:
There were no significant differences between the 2 groups considering age, age of onset of hair loss, family history and type of hair loss (p > 0.05). In the clinical evaluation at the endpoint of treatment, the clinical cure rates (ie increased intensity of hair) were 80% (32/40) for the oral finasteride group and 52% (13/25) for the 5% topical minoxidil group. Encountered side effects were all mild, and there was no need to stop the treatment. In the group given oral finasteride, side effects were noted in 7 patients: 6 patients suffered from loss of libido, and 1 patient had an increase in other body hairs; irritation of the scalp was seen in 1 patient in the group administered 5% minoxidil. These adverse events disappeared as soon as the treatment was stopped. The laboratory data on both drug groups did not show any statistically or clinically significant intragroup changes from baseline values to the endpoint (p > 0.05), except the level of serum total testosterone which was increased, and free testosterone and serum prostate-specific antigen in the finasteride group which were statistically decreased from baseline values to the endpoint (p < 0.05).

CONCLUSION:
In this comparative study of systemic finasteride and topical minoxidil, it was concluded that both drugs were effective and safe in the treatment of mild to severe AGA, although oral finasteride treatment was more effective (p < 0.05). Adverse events were not considered important either, and these side effects disappeared as soon as the treatment was stopped.
finasteride or flutamide of hamster flank organ size and enzyme activity.
Chen C 1 , Puy LA , Simard J , Li X , Singh SM , Labrie F .
Author information
1 MRC Group in Molecular Endocrinology, CHUL Research Center, Québec, Canada.
Abstract
The hamster flank organ is a widely used model of the control of sebaceous gland activity by androgens and anti-androgens. Finasteride, a 5 alpha-reductase inhibitor, was administered locally on the surface of the right flank organ and right ear twice daily for 4 weeks. The treatment caused similar 12% to 30% reductions in the size of the sebaceous glands in both flank organs. Moreover, relative mRNA levels of the androgen-regulated FAR-17a gene measured by in situ hybridization as well as [3H]-thymidine incorporation and 5 alpha-reductase activity were similarly decreased in the two flank organs after topical application. The pure anti-androgen flutamide, at the same doses, exerted a more potent effect on all the same parameters, and the effect was also comparable on both the treated and untreated sides of flank organs. Finasteride and flutamide significantly decreased ventral and dorsal prostatic weights after topical application. The present data show that the topical administration of finasteride, in analogy with flutamide, causes local inhibition of sebaceous gland growth in both the costovertebral organs and ears. However, as demonstrated by the similar inhibitory effect in the contralateral untreated side and the reduced weight of the dorsal and ventral lobes of the prostate and seminal vesicles, finasteride and flutamide both exert significant systemic effects.


PMID: 15316165 [PubMed - indexed for MEDLINE] şu başka calısma

Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation.
Kumar R 1 , Singh B , Bakshi G , Katare OP .
Author information
1 University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Abstract
Finasteride (FNS) is a "drug of choice" for benign prostate hypertrophy and prostate cancer. The drug has also been reported to be useful orally in the treatment of some difficult-to-treat androgen-dependent skin disorders, such as seborrhea, acne, hirsutism, and androgenetic alopecia. However, the ideal route for its administration (ie, topical) remains unexplored. This has logically suggested the search for strategic formulation approaches to make the drug effective on topical applications, hitherto unexplored. The present study targets the encasement of drug molecules in the interiors of vesicular compartments (liposomes) made up of hydrogenated phospholipids, as an attempt toward the development of a trans-epidermal therapeutic system of FNS. Multilamellar drug-loaded liposomes were prepared by thin-film hydration with sonication method and optimized with respect to drug payload, entrapment efficiency, and size by formulating different vesicular compositions under different process conditions. The vesicular systems consisting of saturated phospholipid (100 mg), cholesterol (50 mg), and FNS (5 mg) showed highest drug payload (2.9 mg/100 mg of total lipids), and drug entrapment efficiency (88.6%). Mean (+/-SD) vesicle size of the prepared liposomes was found to be 3.66+/-1.6 microm. Significantly higher skin permeation of FNS through excised abdominal mice skin of FNS was achieved from the liposomal formulations vis-à-vis corresponding solution and conventional gels. Liposomal FNS formulations also showed more than fivefold higher deposition of drug in skin than the corresponding plain drug solution and conventional gel. Stability studies indicated that the liposomal formulations were quite stable in the refrigerated conditions for 2 months with negligible drug leakage or vesicle size alteration during the storage period. Results of the current studies with FNS-loaded vesicular systems project the high plausibility of a topical liposomal formulation for effective localized delivery of Finasteride.

A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.
Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R.
Abstract
OBJECTIVE:
Finasteride, a selective inhibitor of type 2 5-alpha reductase isoenzyme, inhibits the conversion of testosterone to dihydrotestosterone (DHT) and is indicated in the treatment of male androgenetic alopecia. The study objective was to evaluate a newly developed finasteride 0.25% topical solution in comparison to the marketed finasteride 1 mg tablet, with respect to finasteride pharmacokinetics and suppressive effects on plasma DHT.
METHODS:
24 healthy men with androgenetic alopecia were randomized in a single center, open-label, parallel-group, exploratory study, and received either multiple scalp applications of the topical solution b.i.d. or oral doses of the reference tablet o.d. for 7 days. Plasma finasteride, testosterone and DHT concentrations were determined.
RESULTS:
After multiple doses, mean (± SD) finasteride Cmax and AUC0-t corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet. Plasma DHT was reduced by ~ 68 - 75% with the topical solution and by ~ 62 - 72% with the tablet. No relevant changes occurred for plasma testosterone with either treatment. No clinically significant adverse events occurred.
CONCLUSIONS:
A strong and similar inhibition of plasma DHT was found after 1 week of treatment with the topical and tablet finasteride ormulations, albeit finasteride plasma exposure was significantly lower with the topical than with the oral product (p < 0.0001).

PMID: 18161632 [PubMed - indexed for MEDLINE]

[bendeniz]

şunlardan birimi miracle cevirdim googlden ama anlamadım dun gece bashettigim calısmayı gormustum

[bendeniz]

yada su olabilir Pharmacodynamic of P-3074 (finasteride 0.25 % topical solution) in subjects with androgenetic alopecia
M Caserini 1 , R Palmieri 1 , M Radicioni 2 and E Terragni 2 1 Polichem SA, Lugano, Switzerland and 2 Cross Research SA, Arzo, Switzerland
A new proprietary topical formulation, P-3074, containing finasteride 0.25 % as active ingredient and hydroxypropyl-chitosan (HPCH) as film-forming agent, was developed for androgenetic alopecia. The present study was aimed at investigating the pharmacodynamic profile of finasteride in terms of dihydrotestosterone (DHT) concentrations in the scalp and in serum after multiple topical application of P-3074 or oral finasteride intake in subjects with androgenetic alopecia. Eighteen healthy men were randomly allocated to P-3074 or oral treatment after providing written informed consent. Twelve volunteers applied P-3074 topical solution for 7 days: six subjects once daily (od) in the morning and the others twice daily (bid) in the morning and in the evening. The third group of six volunteers was administered 1   mg oral finasteride once daily in the morning for 1 week. Scalp (vertex) biopsies were collected at baseline and 6   hours after last dose administration, while serum samples were collected at baseline, before last administration, and 6 and 12   hours after the last multiple dose. A marked decrease in scalp DHT levels was observed: by 47.22 % with P-3074 bid, from 1.91 (±0.54) to 1.01   ng   ml −1 (±0.39), by 71.20 % with P-3074 od, from 1.52 (±0.41) to 0.44   ng   ml −1 (±0.08), and by 51.11 % with the oral formulation, from 1.39 (±0.25) to 0.68   ng   ml −1 (±0.34). Serum DHT was reduced by 69.3–74.0 % with P-3074 bid, 67.6–80.4 % with P-3074 od, and 69.7–76.1 % with the oral formulation. These results showed a similar inhibition of serum DHT after 1 week of finasteride administration with the three dose regimens and were consistent with the results obtained in a previous P-3074 PK study. These findings show that DHT concentration in the scalp, after 7-day treatment course of P-3074 od, was more reduced (about 40 % ) than after 1   mg oral finasteride administration for the same treatment period.